Application of four pricing models for orphan medicines: a case study for lumasiran

Abstract Background The combination of high prices and uncertain effectiveness is a growing challenge in the field of orphan medicines, hampering health technology assessments. Hence, new methods for establishing price benchmarks might be necessary to support reimbursement negotiations. In this stud...

Full description

Bibliographic Details
Published in:Orphanet Journal of Rare Diseases
Main Authors: Noa Rosenberg, Evert Manders, Sibren van den Berg, Lisa J. Deesker, Sander F. Garrelfs, Saco J. de Visser, Jaap W. Groothoff, Carla E. M. Hollak
Format: Article
Language:English
Published: BMC 2024-12-01
Subjects:
Pricing models
Lumasiran
Orphan medicinal products
Primary hyperoxaluria type 1
Online Access:https://doi.org/10.1186/s13023-024-03446-w

Internet

https://doi.org/10.1186/s13023-024-03446-w

Similar Items